Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)

• Main Authors: Mario Valenti (Author), Luigi Gargiulo (Author), Luciano Ibba (Author), Piergiorgio Malagoli (Author), Fabrizio Amoruso (Author), Anna Balato (Author), Federico Bardazzi (Author), Martina Burlando (Author), Carlo G. Carrera (Author), Paolo Dapavo (Author), Valentina Dini (Author), Francesca M. Gaiani (Author), Giampiero Girolomoni (Author), Claudio Guarneri (Author), Claudia Lasagni (Author), Francesco Loconsole (Author), Angelo V. Marzano (Author), Martina Maurelli (Author), Matteo Megna (Author), Diego Orsini (Author), Massimo Travaglini (Author), Antonio Costanzo (Author), Alessandra Narcisi (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Abstract Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safety in both clinical trials and real-world experiences. However, there is a lack of long-term real-world data available for ixekizumab. Methods We conducted a multicenter real-life study to evaluate the effectiveness and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis. Psoriasis Area and Severity Index score (PASI) was collected at baseline and after 1, 2, 3, 4, and 5 years. The occurrence of any adverse events was recorded at each time point. Results We enrolled 1096 patients treated with ixekizumab for at least 1 year. At week 52, the percentages of PASI 90 and PASI 100 were 85.04% and 69.07%, respectively. After 5 years of treatment with ixekizumab, out of 145 patients, a PASI 90 response was achieved by 86.90% of patients, while complete skin clearance was reached by 68.28% of patients. We did not observe any new significant safety findings throughout the study period. Conclusion This study supports the long-term effectiveness and safety of ixekizumab in a real-world setting.

Item Description

10.1007/s13555-024-01182-4
2193-8210
2190-9172